In juvenile idiopathic arthritis, immunisation and vaccine safetyAuthor(s): Glen Hazelwood
Autoimmune mechanisms and medicines used in treatment increase the threat of liver complaint in cases with juvenile idiopathic arthritis (JIA) and hepatitis A contagion (HAV) vaccination is important, especially in intermediate- endemicity areas like Turkey. In our study, we aimed to estimate the vulnerable response to hepatitis A vaccine and vaccine safety in children with JIA.
This study was carried out in our sanitarium’s Pediatric Rheumatology inpatient clinic and Healthy Child clinic between the times 2003 and 2008. The study group comported of 47 children with JIA (23 joker and 24 womanish) diagnosed according to International League of Associations for Rheumatology individual criteria. The control group comported of 67 healthy children (31 ladies, 36 manly) who didn't have a history of hepatitis A infection or vaccination. Both groups were vaccinated with two boluses of hepatitis A vaccine at 6- month intervals. Anti-HAV IgG> 80 MIU was accepted as positive response.
There was no significant difference between the groups in terms of age and coitus. None of the cases with JIA had fever, clinical worsening, or complaint activation after vaccination. Anti-HAV IgG positivity rate was significantly advanced in the control group (p<0.05). Anti-HAV IgG was negative in only four cases, and they were all manly cases with systemic JIA who had active complaint underanti-tumor necrosis factor treatment.
Hepatitis A vaccine was safe in cases with JIA, and response to vaccine didn't differ between healthy children and cases with JIA except for children with active systemic JIA enteringanti-tumor necrosis factor nascence medicines.